Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company whose news flow centers on its NMDA-based drug pipeline and interventional psychiatry operations. Company announcements frequently highlight progress with NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral D-cycloserine/lurasidone combination, both aimed at serious central nervous system disorders such as suicidal depression and suicidal bipolar depression.
Investors following NRXP news can expect updates on FDA interactions, including Fast Track and Breakthrough Therapy designations, Abbreviated New Drug Application (ANDA) milestones for preservative-free ketamine, and New Drug Application (NDA) activities. The company also reports on the use of large Real World Evidence datasets to support potential Accelerated Approval pathways for NRX-100 in suicidal ideation associated with depression and bipolar depression.
Another recurring theme in NRx Pharmaceuticals’ news is the expansion of its HOPE Therapeutics subsidiary, which operates interventional psychiatry clinics. Releases describe clinic acquisitions, strategic interests in practices, and deployment of treatments such as ketamine-based therapies, Transcranial Magnetic Stimulation (TMS), Hyperbaric Oxygen Therapy, and digital therapeutics for suicidal depression, PTSD, and related conditions. Updates often cover new treatment protocols that combine TMS with D-cycloserine and other medications.
NRXP news items also include corporate developments such as conference presentations, corporate update calls, financing transactions, and changes in independent registered public accounting firms, as reflected in SEC filings. For investors and observers, the news stream provides ongoing insight into NRx Pharmaceuticals’ clinical progress, regulatory steps, clinic network growth, and capital markets activity related to its focus on Neuroplastic Therapies and suicidal depression.
NRx Pharmaceuticals, Inc. (NRx Pharmaceuticals) will participate in the EF Hutton Annual Global Conference on May 15, 2024, in New York City. Prof. Jonathan Javitt, MD, MPH, and Matthew Duffy will meet with investors.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) will report its first quarter 2024 financial results on May 14, 2024. The Company, a clinical-stage biopharmaceutical firm, will share the results via a press release and host a conference call to discuss them and provide a corporate update.
NRx Pharmaceuticals (NRXP) has announced final clinical trial results showing a superior safety profile of NRX-101 compared to Lurasidone in treating suicidal bipolar depression. NRX-101 demonstrated a 76% reduction in akathisia symptoms with essentially zero levels at day 42, while also seeking accelerated FDA approval for use in patients at risk of akathisia. The study will be presented at the ASCP meeting in May 2024.
NRx Pharmaceuticals (NRXP) announced promising findings in a Phase 2b/3 clinical trial of NRX-101 vs. Lurasidone for the treatment of suicidal bipolar depression. NRX-101 demonstrated a 33% advantage in sustained remission in suicidality and a 75% advantage in relief from Akathisia compared to Lurasidone. Data from the study support an approval pathway for NRX-101 to become a standard of care in the treatment of bipolar depression. The trial showed comparable results to previous trials and expanded the potential utility of NRx-101 for a larger patient population. The company aims to change the treatment paradigm for patients with a high suicide risk, providing a potential blockbuster drug.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.